Lenox Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Lenox Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$1K	Hold	140	–	–	﹤0.01%	707
2020 Q1	$1K	Hold	140	–	–	﹤0.01%	677
2019 Q4	$1K	Hold	140	–	–	﹤0.01%	684
2019 Q3	$0	Sell	140 -236	-63%	-$1.81K	﹤0.01%	729
2019 Q2	$3K	Hold	376	–	–	﹤0.01%	572
2019 Q1	$6K	Hold	376	–	–	﹤0.01%	500
2018 Q4	$6K	Hold	376	–	–	﹤0.01%	451
2018 Q3	$8K	Hold	376	–	–	﹤0.01%	443
2018 Q2	$9K	Hold	376	–	–	﹤0.01%	381
2018 Q1	$6K	Hold	376	–	–	﹤0.01%	394
2017 Q4	$7K	Hold	376	–	–	﹤0.01%	411
2017 Q3	$6K	Hold	376	–	–	﹤0.01%	438
2017 Q2	$12K	Hold	376	–	–	﹤0.01%	357
2017 Q1	$12K	Sell	376 -88	-19%	-$3K	0.01%	161
2016 Q4	$17K	Buy	464 +88	+23%	+$3.51K	0.01%	146
2016 Q3	$17K	Hold	376	–	–	0.01%	149
2016 Q2	$19K	Buy	376 +236	+169%	+$12.6K	0.01%	145
2016 Q1	$7K	Hold	140	–	–	﹤0.01%	180
2015 Q4	$9K	Buy	+140	New	+$8.65K	0.01%	171

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lenox Wealth Management's TEVA Position: Q2 2020 in Review

Lenox Wealth Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2020 at 140 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #707.

Lenox Wealth Management first reported a position in TEVA in Q4 2015 and has held it in 19 quarters since. The position peaked at $19K in Q2 2016. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

Lenox Wealth Management held 140 shares of Teva Pharmaceuticals worth $1K as of Q2 2020.
Lenox Wealth Management left its Teva Pharmaceuticals share count unchanged in Q2 2020.
Teva Pharmaceuticals made up ﹤0.01% of Lenox Wealth Management's portfolio in Q2 2020, its #707 holding.
Lenox Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 19 quarters since.
Lenox Wealth Management's Teva Pharmaceuticals position peaked at $19K in Q2 2016.
455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on Lenox Wealth Management's 13F filing for Q2 2020, filed 28 Jul 2020.